APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiple Sclerosis (MS) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Multiple Sclerosis (MS) Drugs Market Outlook and Growth Opportunities 2026

26 December 2025206 pages

Choose your research edition.

Industry ResearchMultiple Sclerosis (MS) Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Sclerosis (MS) Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Multiple Sclerosis (MS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Sclerosis (MS) Drugs Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Sclerosis (MS) Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Multiple Sclerosis (MS) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Multiple Sclerosis (MS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multiple Sclerosis (MS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multiple Sclerosis (MS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Multiple Sclerosis (MS) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Multiple Sclerosis (MS) Drugs market include Eli Lilly, Bayer AG, Innate Immunotherapeutics, Gw Pharmaceuticals, Glaxosmithkline, Genzyme, Genmab, Five Prime Therapeutics and Fast Forward Llc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Multiple Sclerosis (MS) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multiple Sclerosis (MS) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multiple Sclerosis (MS) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Multiple Sclerosis (MS) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Multiple Sclerosis (MS) Drugs Segment by Company

Eli Lilly

Bayer AG

Innate Immunotherapeutics

Gw Pharmaceuticals

Glaxosmithkline

Genzyme

Genmab

Five Prime Therapeutics

Fast Forward Llc

Daiichi Sankyo

Cinnagen

Biogen Idec

Bayhill Therapeutics

Artielle Immunotherapeutics

Apitope

Antisense Therapeutics

Multiple Sclerosis (MS) Drugs Segment by Type

Copaxone (Glatiramer Acetate, Copolymer 1)

Firategrast (Sb683699, T-0047)

Gilenya (Fingolimod, Fty720)

Tecfidera (Dimethyl Fumarate)

Aubagio (Teriflunomide)

Siponimod (Baf312)

Novantrone (Mitoxantrone)

Others

Multiple Sclerosis (MS) Drugs Segment by Application

PPMS

PRMS

RRMS

SPMS

Multiple Sclerosis (MS) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Multiple Sclerosis (MS) Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Multiple Sclerosis (MS) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Multiple Sclerosis (MS) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Multiple Sclerosis (MS) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis (MS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis (MS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis (MS) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multiple Sclerosis (MS) Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multiple Sclerosis (MS) Drugs industry.

Chapter 3: Detailed analysis of Multiple Sclerosis (MS) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Multiple Sclerosis (MS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Multiple Sclerosis (MS) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Multiple Sclerosis (MS) Drugs Industry Trends Table 2. Multiple Sclerosis (MS) Drugs Industry Drivers Table 3. Multiple Sclerosis (MS) Drugs Industry Opportunities and Challenges Table 4. Multiple Sclerosis (MS) Drugs Industry Restraints Table 5. Global Multiple Sclerosis (MS) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Multiple Sclerosis (MS) Drugs Revenue Share by Company (2021-2026) Table 7. Global Multiple Sclerosis (MS) Drugs Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Multiple Sclerosis (MS) Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Multiple Sclerosis (MS) Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Multiple Sclerosis (MS) Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Multiple Sclerosis (MS) Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Multiple Sclerosis (MS) Drugs Company, Product Type & Application Table 13. Global Multiple Sclerosis (MS) Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Multiple Sclerosis (MS) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Copaxone (Glatiramer Acetate, Copolymer 1) Table 18. Significant Companies of Firategrast (Sb683699, T-0047) Table 19. Significant Companies of Gilenya (Fingolimod, Fty720) Table 20. Significant Companies of Tecfidera (Dimethyl Fumarate) Table 21. Significant Companies of Aubagio (Teriflunomide) Table 22. Significant Companies of Siponimod (Baf312) Table 23. Significant Companies of Novantrone (Mitoxantrone) Table 24. Significant Companies of Others Table 25. Global Multiple Sclerosis (MS) Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 26. Global Multiple Sclerosis (MS) Drugs Sales Volume by Type (2021-2026) & (W Units) Table 27. Global Multiple Sclerosis (MS) Drugs Sales Volume by Type (2027-2032) & (W Units) Table 28. Global Multiple Sclerosis (MS) Drugs Sales Volume Share by Type (2021-2026) Table 29. Global Multiple Sclerosis (MS) Drugs Sales Volume Share by Type (2027-2032) Table 30. Global Multiple Sclerosis (MS) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Multiple Sclerosis (MS) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 32. Global Multiple Sclerosis (MS) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 33. Global Multiple Sclerosis (MS) Drugs Sales Value Share by Type (2021-2026) Table 34. Global Multiple Sclerosis (MS) Drugs Sales Value Share by Type (2027-2032) Table 35. Significant Companies of PPMS Table 36. Significant Companies of PRMS Table 37. Significant Companies of RRMS Table 38. Significant Companies of SPMS Table 39. Global Multiple Sclerosis (MS) Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 40. Global Multiple Sclerosis (MS) Drugs Sales Volume by Application (2021-2026) & (W Units) Table 41. Global Multiple Sclerosis (MS) Drugs Sales Volume by Application (2027-2032) & (W Units) Table 42. Global Multiple Sclerosis (MS) Drugs Sales Volume Share by Application (2021-2026) Table 43. Global Multiple Sclerosis (MS) Drugs Sales Volume Share by Application (2027-2032) Table 44. Global Multiple Sclerosis (MS) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Multiple Sclerosis (MS) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 46. Global Multiple Sclerosis (MS) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 47. Global Multiple Sclerosis (MS) Drugs Sales Value Share by Application (2021-2026) Table 48. Global Multiple Sclerosis (MS) Drugs Sales Value Share by Application (2027-2032) Table 49. Global Multiple Sclerosis (MS) Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 50. Global Multiple Sclerosis (MS) Drugs Sales by Region (2021-2026) & (W Units) Table 51. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2021-2026) Table 52. Global Multiple Sclerosis (MS) Drugs Sales by Region (2027-2032) & (W Units) Table 53. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2027-2032) Table 54. Global Multiple Sclerosis (MS) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Multiple Sclerosis (MS) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 56. Global Multiple Sclerosis (MS) Drugs Sales Value Share by Region (2021-2026) Table 57. Global Multiple Sclerosis (MS) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 58. Global Multiple Sclerosis (MS) Drugs Sales Value Share by Region (2027-2032) Table 59. Global Multiple Sclerosis (MS) Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 60. Global Multiple Sclerosis (MS) Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 61. Global Multiple Sclerosis (MS) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 62. Global Multiple Sclerosis (MS) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 64. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2026) Table 65. Global Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 66. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2027-2032) Table 67. Global Multiple Sclerosis (MS) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 68. Global Multiple Sclerosis (MS) Drugs Sales Value Market Share by Country (2021-2026) Table 69. Global Multiple Sclerosis (MS) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 70. Global Multiple Sclerosis (MS) Drugs Sales Value Market Share by Country (2027-2032) Table 71. Eli Lilly Company Information Table 72. Eli Lilly Business Overview Table 73. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio Table 75. Eli Lilly Recent Development Table 76. Bayer AG Company Information Table 77. Bayer AG Business Overview Table 78. Bayer AG Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio Table 80. Bayer AG Recent Development Table 81. Innate Immunotherapeutics Company Information Table 82. Innate Immunotherapeutics Business Overview Table 83. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 85. Innate Immunotherapeutics Recent Development Table 86. Gw Pharmaceuticals Company Information Table 87. Gw Pharmaceuticals Business Overview Table 88. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio Table 90. Gw Pharmaceuticals Recent Development Table 91. Glaxosmithkline Company Information Table 92. Glaxosmithkline Business Overview Table 93. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio Table 95. Glaxosmithkline Recent Development Table 96. Genzyme Company Information Table 97. Genzyme Business Overview Table 98. Genzyme Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio Table 100. Genzyme Recent Development Table 101. Genmab Company Information Table 102. Genmab Business Overview Table 103. Genmab Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Genmab Multiple Sclerosis (MS) Drugs Product Portfolio Table 105. Genmab Recent Development Table 106. Five Prime Therapeutics Company Information Table 107. Five Prime Therapeutics Business Overview Table 108. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 110. Five Prime Therapeutics Recent Development Table 111. Fast Forward Llc Company Information Table 112. Fast Forward Llc Business Overview Table 113. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio Table 115. Fast Forward Llc Recent Development Table 116. Daiichi Sankyo Company Information Table 117. Daiichi Sankyo Business Overview Table 118. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio Table 120. Daiichi Sankyo Recent Development Table 121. Cinnagen Company Information Table 122. Cinnagen Business Overview Table 123. Cinnagen Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio Table 125. Cinnagen Recent Development Table 126. Biogen Idec Company Information Table 127. Biogen Idec Business Overview Table 128. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio Table 130. Biogen Idec Recent Development Table 131. Bayhill Therapeutics Company Information Table 132. Bayhill Therapeutics Business Overview Table 133. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 135. Bayhill Therapeutics Recent Development Table 136. Artielle Immunotherapeutics Company Information Table 137. Artielle Immunotherapeutics Business Overview Table 138. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 140. Artielle Immunotherapeutics Recent Development Table 141. Apitope Company Information Table 142. Apitope Business Overview Table 143. Apitope Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Apitope Multiple Sclerosis (MS) Drugs Product Portfolio Table 145. Apitope Recent Development Table 146. Antisense Therapeutics Company Information Table 147. Antisense Therapeutics Business Overview Table 148. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 150. Antisense Therapeutics Recent Development Table 151. Key Raw Materials Table 152. Raw Materials Key Suppliers Table 153. Multiple Sclerosis (MS) Drugs Distributors List Table 154. Multiple Sclerosis (MS) Drugs Customers List Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Multiple Sclerosis (MS) Drugs Product Image Figure 2. Global Multiple Sclerosis (MS) Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiple Sclerosis (MS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Multiple Sclerosis (MS) Drugs Sales (2021-2032) & (W Units) Figure 5. Global Multiple Sclerosis (MS) Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Multiple Sclerosis (MS) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Copaxone (Glatiramer Acetate, Copolymer 1) Image Figure 10. Firategrast (Sb683699, T-0047) Image Figure 11. Gilenya (Fingolimod, Fty720) Image Figure 12. Tecfidera (Dimethyl Fumarate) Image Figure 13. Aubagio (Teriflunomide) Image Figure 14. Siponimod (Baf312) Image Figure 15. Novantrone (Mitoxantrone) Image Figure 16. Others Image Figure 17. Global Multiple Sclerosis (MS) Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Multiple Sclerosis (MS) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 19. Global Multiple Sclerosis (MS) Drugs Sales Volume Share by Type (2021-2032) Figure 20. Global Multiple Sclerosis (MS) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Multiple Sclerosis (MS) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Multiple Sclerosis (MS) Drugs Sales Value Share by Type (2021-2032) Figure 23. PPMS Image Figure 24. PRMS Image Figure 25. RRMS Image Figure 26. SPMS Image Figure 27. Global Multiple Sclerosis (MS) Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 28. Global Multiple Sclerosis (MS) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 29. Global Multiple Sclerosis (MS) Drugs Sales Volume Share by Application (2021-2032) Figure 30. Global Multiple Sclerosis (MS) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Multiple Sclerosis (MS) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 32. Global Multiple Sclerosis (MS) Drugs Sales Value Share by Application (2021-2032) Figure 33. Global Multiple Sclerosis (MS) Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 34. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 35. Global Multiple Sclerosis (MS) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 36. Global Multiple Sclerosis (MS) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 37. North America Multiple Sclerosis (MS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. North America Multiple Sclerosis (MS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Europe Multiple Sclerosis (MS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Europe Multiple Sclerosis (MS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. South America Multiple Sclerosis (MS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 44. South America Multiple Sclerosis (MS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 45. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 46. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 47. USA Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. USA Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. USA Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Canada Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Canada Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Canada Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Mexico Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Mexico Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Mexico Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Germany Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Germany Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Germany Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. France Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. France Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. France Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. U.K. Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. U.K. Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. U.K. Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Italy Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Italy Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Italy Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Spain Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Spain Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Spain Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Russia Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Russia Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Russia Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Netherlands Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Netherlands Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Netherlands Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Nordic Countries Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Nordic Countries Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Nordic Countries Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. China Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. China Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. China Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Japan Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Japan Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Japan Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. South Korea Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. South Korea Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. South Korea Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. India Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. India Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. India Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Australia Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Australia Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Australia Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Southeast Asia Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Southeast Asia Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Southeast Asia Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Brazil Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Brazil Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Brazil Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Argentina Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Argentina Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Argentina Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Chile Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Chile Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Chile Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Colombia Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Colombia Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Colombia Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Peru Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Peru Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Peru Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Saudi Arabia Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Saudi Arabia Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Israel Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Israel Arabia Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Israel Arabia Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. UAE Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. UAE Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. UAE Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Turkey Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Turkey Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Turkey Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Iran Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Iran Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Iran Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Egypt Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 129. Egypt Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 130. Egypt Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 131. Multiple Sclerosis (MS) Drugs Value Chain Figure 132. Manufacturing Cost Structure Figure 133. Multiple Sclerosis (MS) Drugs Sales Mode & Process Figure 134. Direct Comparison with Distribution Share Figure 135. Distributors Profiles Figure 136. Years Considered Figure 137. Research Process Figure 138. Key Executives Interviewed

Scope & coverage.

Types
  • Copaxone (Glatiramer Acetate, Copolymer 1)
  • Firategrast (Sb683699, T-0047)
  • Gilenya (Fingolimod, Fty720)
  • Tecfidera (Dimethyl Fumarate)
  • Aubagio (Teriflunomide)
  • Siponimod (Baf312)
  • Novantrone (Mitoxantrone)
  • Others
Applications
  • PPMS
  • PRMS
  • RRMS
  • SPMS
Companies covered
  • Eli Lilly
  • Bayer AG
  • Innate Immunotherapeutics
  • Gw Pharmaceuticals
  • Glaxosmithkline
  • Genzyme
  • Genmab
  • Five Prime Therapeutics
  • Fast Forward Llc
  • Daiichi Sankyo
  • Cinnagen
  • Biogen Idec
  • Bayhill Therapeutics
  • Artielle Immunotherapeutics
  • Apitope
  • Antisense Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Multiple Sclerosis (MS) Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Multiple Sclerosis (MS) Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Multiple Sclerosis (MS) Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Multiple Sclerosis (MS) Drugs Market Dynamics
  1. 2.1 Multiple Sclerosis (MS) Drugs Industry Trends
  2. 2.2 Multiple Sclerosis (MS) Drugs Industry Drivers
  3. 2.3 Multiple Sclerosis (MS) Drugs Industry Opportunities and Challenges
  4. 2.4 Multiple Sclerosis (MS) Drugs Industry Restraints
3 Multiple Sclerosis (MS) Drugs Market by Company
  1. 3.1 Global Multiple Sclerosis (MS) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Multiple Sclerosis (MS) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Multiple Sclerosis (MS) Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Multiple Sclerosis (MS) Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Multiple Sclerosis (MS) Drugs Company Ranking (2024-2026)
  6. 3.6 Global Multiple Sclerosis (MS) Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Multiple Sclerosis (MS) Drugs Company Product Type and Application
  8. 3.8 Global Multiple Sclerosis (MS) Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Multiple Sclerosis (MS) Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Multiple Sclerosis (MS) Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Multiple Sclerosis (MS) Drugs Market by Type
  1. 4.1 Multiple Sclerosis (MS) Drugs Type Introduction
  2. 4.1.1 Copaxone (Glatiramer Acetate, Copolymer 1)
  3. 4.1.2 Firategrast (Sb683699, T-0047)
  4. 4.1.3 Gilenya (Fingolimod, Fty720)
  5. 4.1.4 Tecfidera (Dimethyl Fumarate)
  6. 4.1.5 Aubagio (Teriflunomide)
  7. 4.1.6 Siponimod (Baf312)
  8. 4.1.7 Novantrone (Mitoxantrone)
  9. 4.1.8 Others
  10. 4.2 Global Multiple Sclerosis (MS) Drugs Sales Volume by Type
  11. 4.2.1 Global Multiple Sclerosis (MS) Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Multiple Sclerosis (MS) Drugs Sales Volume by Type (2021-2032)
  13. 4.2.3 Global Multiple Sclerosis (MS) Drugs Sales Volume Share by Type (2021-2032)
  14. 4.3 Global Multiple Sclerosis (MS) Drugs Sales Value by Type
  15. 4.3.1 Global Multiple Sclerosis (MS) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Multiple Sclerosis (MS) Drugs Sales Value by Type (2021-2032)
  17. 4.3.3 Global Multiple Sclerosis (MS) Drugs Sales Value Share by Type (2021-2032)
5 Multiple Sclerosis (MS) Drugs Market by Application
  1. 5.1 Multiple Sclerosis (MS) Drugs Application Introduction
  2. 5.1.1 PPMS
  3. 5.1.2 PRMS
  4. 5.1.3 RRMS
  5. 5.1.4 SPMS
  6. 5.2 Global Multiple Sclerosis (MS) Drugs Sales Volume by Application
  7. 5.2.1 Global Multiple Sclerosis (MS) Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Multiple Sclerosis (MS) Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Multiple Sclerosis (MS) Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Multiple Sclerosis (MS) Drugs Sales Value by Application
  11. 5.3.1 Global Multiple Sclerosis (MS) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Multiple Sclerosis (MS) Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Multiple Sclerosis (MS) Drugs Sales Value Share by Application (2021-2032)
6 Multiple Sclerosis (MS) Drugs Regional Sales and Value Analysis
  1. 6.1 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multiple Sclerosis (MS) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Multiple Sclerosis (MS) Drugs Sales by Region (2027-2032)
  5. 6.3 Global Multiple Sclerosis (MS) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Multiple Sclerosis (MS) Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Multiple Sclerosis (MS) Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Multiple Sclerosis (MS) Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Multiple Sclerosis (MS) Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Multiple Sclerosis (MS) Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Multiple Sclerosis (MS) Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Multiple Sclerosis (MS) Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Multiple Sclerosis (MS) Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Multiple Sclerosis (MS) Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Multiple Sclerosis (MS) Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Value Share by Country, 2025 VS 2032
7 Multiple Sclerosis (MS) Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Multiple Sclerosis (MS) Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Multiple Sclerosis (MS) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Multiple Sclerosis (MS) Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032)
  6. 7.4 Global Multiple Sclerosis (MS) Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Multiple Sclerosis (MS) Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Multiple Sclerosis (MS) Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Multiple Sclerosis (MS) Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Multiple Sclerosis (MS) Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Multiple Sclerosis (MS) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly
  2. 8.1.1 Eli Lilly Company Information
  3. 8.1.2 Eli Lilly Business Overview
  4. 8.1.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio
  6. 8.1.5 Eli Lilly Recent Developments
  7. 8.2 Bayer AG
  8. 8.2.1 Bayer AG Company Information
  9. 8.2.2 Bayer AG Business Overview
  10. 8.2.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio
  12. 8.2.5 Bayer AG Recent Developments
  13. 8.3 Innate Immunotherapeutics
  14. 8.3.1 Innate Immunotherapeutics Company Information
  15. 8.3.2 Innate Immunotherapeutics Business Overview
  16. 8.3.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  18. 8.3.5 Innate Immunotherapeutics Recent Developments
  19. 8.4 Gw Pharmaceuticals
  20. 8.4.1 Gw Pharmaceuticals Company Information
  21. 8.4.2 Gw Pharmaceuticals Business Overview
  22. 8.4.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio
  24. 8.4.5 Gw Pharmaceuticals Recent Developments
  25. 8.5 Glaxosmithkline
  26. 8.5.1 Glaxosmithkline Company Information
  27. 8.5.2 Glaxosmithkline Business Overview
  28. 8.5.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio
  30. 8.5.5 Glaxosmithkline Recent Developments
  31. 8.6 Genzyme
  32. 8.6.1 Genzyme Company Information
  33. 8.6.2 Genzyme Business Overview
  34. 8.6.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio
  36. 8.6.5 Genzyme Recent Developments
  37. 8.7 Genmab
  38. 8.7.1 Genmab Company Information
  39. 8.7.2 Genmab Business Overview
  40. 8.7.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Genmab Multiple Sclerosis (MS) Drugs Product Portfolio
  42. 8.7.5 Genmab Recent Developments
  43. 8.8 Five Prime Therapeutics
  44. 8.8.1 Five Prime Therapeutics Company Information
  45. 8.8.2 Five Prime Therapeutics Business Overview
  46. 8.8.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  48. 8.8.5 Five Prime Therapeutics Recent Developments
  49. 8.9 Fast Forward Llc
  50. 8.9.1 Fast Forward Llc Company Information
  51. 8.9.2 Fast Forward Llc Business Overview
  52. 8.9.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio
  54. 8.9.5 Fast Forward Llc Recent Developments
  55. 8.10 Daiichi Sankyo
  56. 8.10.1 Daiichi Sankyo Company Information
  57. 8.10.2 Daiichi Sankyo Business Overview
  58. 8.10.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio
  60. 8.10.5 Daiichi Sankyo Recent Developments
  61. 8.11 Cinnagen
  62. 8.11.1 Cinnagen Company Information
  63. 8.11.2 Cinnagen Business Overview
  64. 8.11.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio
  66. 8.11.5 Cinnagen Recent Developments
  67. 8.12 Biogen Idec
  68. 8.12.1 Biogen Idec Company Information
  69. 8.12.2 Biogen Idec Business Overview
  70. 8.12.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio
  72. 8.12.5 Biogen Idec Recent Developments
  73. 8.13 Bayhill Therapeutics
  74. 8.13.1 Bayhill Therapeutics Company Information
  75. 8.13.2 Bayhill Therapeutics Business Overview
  76. 8.13.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  78. 8.13.5 Bayhill Therapeutics Recent Developments
  79. 8.14 Artielle Immunotherapeutics
  80. 8.14.1 Artielle Immunotherapeutics Company Information
  81. 8.14.2 Artielle Immunotherapeutics Business Overview
  82. 8.14.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  84. 8.14.5 Artielle Immunotherapeutics Recent Developments
  85. 8.15 Apitope
  86. 8.15.1 Apitope Company Information
  87. 8.15.2 Apitope Business Overview
  88. 8.15.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Apitope Multiple Sclerosis (MS) Drugs Product Portfolio
  90. 8.15.5 Apitope Recent Developments
  91. 8.16 Antisense Therapeutics
  92. 8.16.1 Antisense Therapeutics Company Information
  93. 8.16.2 Antisense Therapeutics Business Overview
  94. 8.16.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  96. 8.16.5 Antisense Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Multiple Sclerosis (MS) Drugs Value Chain Analysis
  2. 9.1.1 Multiple Sclerosis (MS) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Multiple Sclerosis (MS) Drugs Sales Mode & Process
  6. 9.2 Multiple Sclerosis (MS) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Multiple Sclerosis (MS) Drugs Distributors
  9. 9.2.3 Multiple Sclerosis (MS) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst